Form 4: Maravai LifeSciences Executive Christine Dolan Reports Stock Transaction

Christine Dolan, an executive at Maravai LifeSciences, reported the disposal of 5,383 shares of Class A Common Stock to cover tax obligations related to vesting restricted stock units.

Summary

• On March 15, 2024, Christine Dolan, Executive Vice President & General Manager, Cygnus Technologies at Maravai LifeSciences Holdings, Inc., disposed of 5,383 shares of Class A Common Stock.
• The shares were sold at a price of $7.7 per share.
• This transaction was to satisfy tax withholding obligations related to the vesting of restricted stock unit awards.
• Following the transaction, Dolan directly owns 258,007 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: This is a routine transaction related to tax obligations, so it doesn't significantly impact sentiment. It's a neutral event.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like Christine Dolan, transact in their company's stock. These filings provide transparency into insider activity, which can be a signal to investors.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
• Similar filings are common across companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies, where executives routinely report stock transactions related to compensation and tax obligations.
• The number of shares sold to cover tax obligations is typical for executives receiving stock-based compensation.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a routine sale of shares by an executive to cover tax obligations.
• The filing provides transparency to shareholders regarding insider transactions.

Key Dates